Neuroprotective agents and modulation of temporal lobe epilepsy

Area of Science:

• Neurology
• Neuroscience
• Pharmacology

Background:

• Temporal Lobe Epilepsy (TLE) is a chronic neurological disorder characterized by seizures originating in the temporal lobe.
• Hippocampal sclerosis, marked by significant cell death in the hippocampus, is a key feature of TLE.
• Current antiepileptic drugs (AEDs) are ineffective for 30-40% of patients, and no treatments modify the underlying epileptogenesis process.

Purpose of the Study:

• To review the neuroprotective effects of specific agents.
• To explore disease- and epileptogenesis-modifying potential in TLE.
• To highlight novel therapeutic avenues beyond conventional AEDs.

Main Methods:

• Review of existing literature on adenosinergic agents, erythropoietin, and carisbamate.
• Analysis of studies focusing on neuroprotection and epileptogenesis modification.
• Synthesis of data on the efficacy of these agents in TLE models or patient populations.

Main Results:

• Adenosinergic agents, erythropoietin, and carisbamate demonstrate neuroprotective properties.
• These agents show potential in modifying the epileptogenesis process in TLE.
• Evidence suggests these compounds may offer disease-modifying effects.

Conclusions:

• Adenosinergic agents, erythropoietin, and carisbamate represent promising therapeutic candidates for TLE.
• These agents may offer a new approach to managing TLE by targeting epileptogenesis.
• Further research is warranted to fully elucidate their therapeutic potential in refractory TLE.